<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2024-6140</article-id><article-id custom-type="edn" pub-id-type="custom">WVECZM</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-6140</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИКА И ФАРМАКОТЕРАПИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINIC AND PHARMACOTHERAPY</subject></subj-group></article-categories><title-group><article-title>Факторы риска неприверженности терапии пероральными антикоагулянтами и возможности их коррекции у пациентов с фибрилляцией предсердий (нарративный обзор литературы)</article-title><trans-title-group xml:lang="en"><trans-title>Risk factors for non-adherence to oral anticoagulant therapy and the potential of their modification in patients with atrial fibrillation: a narrative literature review</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4400-0814</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Феликов</surname><given-names>И. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Felikov</surname><given-names>I. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Феликов Игнат Михайлович — региональный медицинский советник.</p><p>Москва</p></bio><bio xml:lang="en"><p>Ignat M. Felikov.</p><p>Moscow</p></bio><email xlink:type="simple">ignat.felikov@bayer.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3729-616X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кашталап</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kashtalap</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кашталап Василий Васильевич — д.м.н., профессор, зав. отделом клинической кардиологии.</p><p>Кемерово</p></bio><bio xml:lang="en"><p>Vasiliy V. Kashtalap.</p><p>Kemerovo</p></bio><email xlink:type="simple">v_kash@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>АО "Байер"</institution><country>Россия</country></aff><aff xml:lang="en"><institution>AO Bayer</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute for Complex Issues of Cardiovascular Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>23</day><month>10</month><year>2024</year></pub-date><volume>29</volume><issue>10</issue><fpage>6140</fpage><lpage>6140</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Феликов И.М., Кашталап В.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Феликов И.М., Кашталап В.В.</copyright-holder><copyright-holder xml:lang="en">Felikov I.M., Kashtalap V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/6140">https://russjcardiol.elpub.ru/jour/article/view/6140</self-uri><abstract><p>Приверженность лечению является ключевым условием эффективности профилактики инсульта у пациентов с фибрилляцией предсердий, получающих терапию оральными антикоагулянтами. При этом с течением времени комплаентность пациентов может значительно снижаться, что приводит к повышению риска тромбоэмболических осложнений. В ряде исследований показано, что большое количество пациентов, получающих антикоагулянтную терапию, недостаточно ей привержены (по данным различных источников от 30 до 50% пациентов не соблюдают предписанный режим лечения, либо прерывают терапию). Независимыми факторами риска некомплаентности являются более молодой возраст, старческий возраст, перенесённый инсульт, мужской пол, полиморбидность, полифармация. Отдельно отмечается риск снижения комплаентности при двукратном применении препарата в сравнении с однократным. Целью данного литературного обзора является изучение факторов риска неприверженности терапии пероральными антикоагулянтами у пациентов с фибрилляцией предсердий и возможные меры её профилактики.</p></abstract><trans-abstract xml:lang="en"><p>Medication adherence is a key factor of effective stroke prevention in patients with atrial fibrillation receiving oral anticoagulant therapy. At the same time, patient compliance can significantly decrease over time, which leads to an increased thromboembolism risk. A number of studies have shown that a large number of patients receiving anticoagulant therapy are insufficiently adherent to therapy (according to various sources, from 30 to 50% of patients do not comply with the prescribed treatment regimen or interrupt therapy).</p><p>Independent risk factors for non-compliance include younger age, old age, prior stroke, male sex, multimorbidity, polypharmacy. The risk of decreased compliance with double drug intake compared to single one is noted separately.</p><p>The review aim is to study the risk factors for non-adherence to oral anticoagulants in patients with atrial fibrillation and possible measures for its prevention.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>приверженность</kwd><kwd>методы диагностики</kwd><kwd>шкалы</kwd><kwd>опросники</kwd><kwd>реальная клиническая практика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>adherence</kwd><kwd>diagnostic methods</kwd><kwd>scales</kwd><kwd>questionnaires</kwd><kwd>clinical practice</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Публикация подготовлена при поддержке АО "Байер".</funding-statement><funding-statement xml:lang="en">The publication was prepared with the support of Bayer.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ozaki AF, Choi AS, Le QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circulation: Cardiovascular Quality and Outcomes. 2020;13(3):e005969. doi:10.1161/CIRCOUTCOMES.119.005969.</mixed-citation><mixed-citation xml:lang="en">Ozaki AF, Choi AS, Le QT, et al. Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. Circulation: Cardiovascular Quality and Outcomes. 2020;13(3):e005969. doi:10.1161/CIRCOUTCOMES.119.005969.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Salmasi S, Loewen PS, Tandun R, et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ open. 2020;10(4):e034778. doi:10.1136/bmjopen-2019-034778.</mixed-citation><mixed-citation xml:lang="en">Salmasi S, Loewen PS, Tandun R, et al. Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies. BMJ open. 2020;10(4):e034778. doi:10.1136/bmjopen-2019-034778.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Desteghe L, Vijgen J, Koopman P, et al. Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation. European heart journal. 2018;39(16):1394-403. doi:10.1093/eurheartj/ehx762.</mixed-citation><mixed-citation xml:lang="en">Desteghe L, Vijgen J, Koopman P, et al. Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation. European heart journal. 2018;39(16):1394-403. doi:10.1093/eurheartj/ehx762.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Márquez-Contreras E, Martell-Claros N, Márquez-Rivero S, et al. Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study). Current medical research and opinion. 2018;34(7):1301-8. doi:10.1080/03007995.2018.1435519.</mixed-citation><mixed-citation xml:lang="en">Márquez-Contreras E, Martell-Claros N, Márquez-Rivero S, et al. Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study). Current medical research and opinion. 2018;34(7):1301-8. doi:10.1080/03007995.2018.1435519.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Николаев Н.А., Мартынов А. И., Скирденко Ю.П. и др. Управление лечением на основе приверженности. Consilium Medicum. 2020;22(5):9-18. doi:10.26442/20751753.2020.5.200078.</mixed-citation><mixed-citation xml:lang="en">Nikolaev NA, Martynov AI, Skirdenko YuP, et al. Management of treatment on the basis of adherence. Consilium Medicum. 2020;22(5):9-18. (In Russ.) doi:10.26442/20751753.2020.5.200078.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">De Geest S, Sabaté E. 2003 Adherence to long-term therapies: evidence for action. European Journal of Cardiovascular Nursing. 2003;2(4):323. doi:10.1016/S1474-5151(03)00091-4.</mixed-citation><mixed-citation xml:lang="en">De Geest S, Sabaté E. 2003 Adherence to long-term therapies: evidence for action. European Journal of Cardiovascular Nursing. 2003;2(4):323. doi:10.1016/S1474-5151(03)00091-4.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Ливзан М.А., Мартынов А. И. и др. Первый Российский консенсус по количественной оценке приверженности к лечению: основные положения, алгоритмы и рекомендации. Медицинский вестник Северного Кавказа. 2018;13(1-2):259-71. doi:10.14300/mnnc.2018.13039.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Livzan MA, Martynov AI, et al. The first Russian expert consensus on the quantitative evaluation of the treatment adherence: pivotal issues, algorithms and recommendations. Medical News of the North Caucasus. 2018;13(1-2):259-71. (In Russ.) doi:10.14300/mnnc.2018.13039.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Maffoni M, Traversoni S, Costa E, et al. Medication adherence in the older adults with chronic multimorbidity: a systematic review of qualitative studies on patient's experience. European geriatric medicine. 2020;11:369-81. doi:10.1007/s41999-020-00313-2.</mixed-citation><mixed-citation xml:lang="en">Maffoni M, Traversoni S, Costa E, et al. Medication adherence in the older adults with chronic multimorbidity: a systematic review of qualitative studies on patient's experience. European geriatric medicine. 2020;11:369-81. doi:10.1007/s41999-020-00313-2.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Visseren FL, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European heart journal. 2021;42(34):3227-37. doi:10.1093/eurjpc/zwab154.</mixed-citation><mixed-citation xml:lang="en">Visseren FL, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European heart journal. 2021;42(34):3227-37. doi:10.1093/eurjpc/zwab154.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chaudri NA. Adherence to Long-term Therapies Evidence for Action. Ann Saudi Med. 2004;24(3):221-2. doi:10.5144/0256-4947.2004.221.</mixed-citation><mixed-citation xml:lang="en">Chaudri NA. Adherence to Long-term Therapies Evidence for Action. Ann Saudi Med. 2004;24(3):221-2. doi:10.5144/0256-4947.2004.221.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18(8):1150-7. doi:10.1093/europace/euv421.</mixed-citation><mixed-citation xml:lang="en">Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18(8):1150-7. doi:10.1093/europace/euv421.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Deshpande CG, Kogut, S, Willey C. Real-world health care costs based on medication adherence and risk of stroke and bleeding in patients treated with novel anticoagulant therapy. Journal of managed care &amp; specialty pharmacy. 2018;24(5):430-9. doi:10.18553/jmcp.2018.24.5.430.</mixed-citation><mixed-citation xml:lang="en">Deshpande CG, Kogut, S, Willey C. Real-world health care costs based on medication adherence and risk of stroke and bleeding in patients treated with novel anticoagulant therapy. Journal of managed care &amp; specialty pharmacy. 2018;24(5):430-9. doi:10.18553/jmcp.2018.24.5.430.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Jackevicius CA, Tsadok MA, Essebag V, et al. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart. 2017;103(17):1331-8. doi:10.1136/heartjnl-2016-310672.</mixed-citation><mixed-citation xml:lang="en">Jackevicius CA, Tsadok MA, Essebag V, et al. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart. 2017;103(17):1331-8. doi:10.1136/heartjnl-2016-310672.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO Library Cataloguing-in-Publication Data, 2003:5-169. ISBN: 9241545992.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO Library Cataloguing-in-Publication Data, 2003:5-169. ISBN: 9241545992.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35. doi:10.1161/CIRCULATIONAHA.108.768986.</mixed-citation><mixed-citation xml:lang="en">Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35. doi:10.1161/CIRCULATIONAHA.108.768986.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Komen JJ, Pottegard A, Mantel-Teeuwisse AK, et al. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace. 2021;23(11):1722-30. doi:10.1093/europace/euab091.</mixed-citation><mixed-citation xml:lang="en">Komen JJ, Pottegard A, Mantel-Teeuwisse AK, et al. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. Europace. 2021;23(11):1722-30. doi:10.1093/europace/euab091.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Лукина Ю. В., Кутишенко Н. П., Марцевич С. Ю. и др. Опросники и шкалы для оценки приверженности к лечению — преимущества и недостатки диагностического метода в научных исследованиях и реальной клинической практике. Кардиоваскулярная терапия и профилактика. 2020;19(3):2562. doi:10.15829/1728-8800-2020-2562.</mixed-citation><mixed-citation xml:lang="en">Lukina YuV, Kutishenko NP, Martsevich SYu, et al. Questionnaires and scores for assessing medication adherence — advantages and disadvantages of the diagnostic method in research and actual clinical practice. Cardiovascular Therapy and Prevention. 2020;19(3):2562. (In Russ.) doi:10.15829/1728-8800-2020-2562.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74. doi:10.1097/00005650-198601000-00007.</mixed-citation><mixed-citation xml:lang="en">Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74. doi:10.1097/00005650-198601000-00007.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Moon SJ, Lee WY, Hwang JS, et al. Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. PLoS One. 2017;12(11):e0187139. doi:10.1371/journal.pone.0187139.</mixed-citation><mixed-citation xml:lang="en">Moon SJ, Lee WY, Hwang JS, et al. Accuracy of a screening tool for medication adherence: A systematic review and meta-analysis of the Morisky Medication Adherence Scale-8. PLoS One. 2017;12(11):e0187139. doi:10.1371/journal.pone.0187139.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sakthong P, Chabunthom R, Charoenvisuthiwongs R. Psychometric properties of the Thai version of the 8-item Morisky Medication Adherence Scale in patients with type 2 diabetes. Ann Pharmacother. 2009;43(5):950-7. doi:10.1345/aph.1L453.</mixed-citation><mixed-citation xml:lang="en">Sakthong P, Chabunthom R, Charoenvisuthiwongs R. Psychometric properties of the Thai version of the 8-item Morisky Medication Adherence Scale in patients with type 2 diabetes. Ann Pharmacother. 2009;43(5):950-7. doi:10.1345/aph.1L453.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Svarstad BL, Chewning BA, Sleath BL, et al. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113-24. doi:10.1016/s0738-3991(98)00107-4.</mixed-citation><mixed-citation xml:lang="en">Svarstad BL, Chewning BA, Sleath BL, et al. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113-24. doi:10.1016/s0738-3991(98)00107-4.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kripalani S, Risser J, Gatti ME, et al. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12(1):118-23. doi:10.1111/j.1524-4733.2008.00400.x.</mixed-citation><mixed-citation xml:lang="en">Kripalani S, Risser J, Gatti ME, et al. Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value Health. 2009;12(1):118-23. doi:10.1111/j.1524-4733.2008.00400.x.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Николаев Н.А., Скирденко Ю. П. Российский универсальный опросник количественной оценки приверженности к лечению (КОП-25). Клиническая фармакология и терапия. 2018;27(1):74-8.</mixed-citation><mixed-citation xml:lang="en">Nikolayev NA, Skirdenko YuP. Russian generic questionnaire for evaluation of compliance to drug therapy. Clin. Pharmacol. Ther. 2018;27(1):74-8. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Лукина Ю.В., Кутишенко Н.П., Толпыгина С.Н. и др. Основные факторы приверженности к приему новых оральных антикоагулянтов и ее динамика у пациентов с неклапанной фибрилляцией предсердий в рамках амбулаторного регистра: результаты исследования АНТЕЙ. Кардиоваскулярная терапия и профилактика. 2020;19(5):2680. doi:10.15829/1728-8800-2020-2680.</mixed-citation><mixed-citation xml:lang="en">Lukina YuV, Kutishenko NP, Tolpygina SN, et al. Main factors of adherence to new oral anticoagulants and its dynamics in outpatients with nonvalvular atrial fibrillation: results of the ANTEY study. Cardiovascular Therapy and Prevention. 2020;19(5):2680. (In Russ.) doi:10.15829/1728-8800-2020-2680.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">van der Horst SF, de Vries TA, Chu G, et al. Prevalence and predictors of nonadherence to direct oral anticoagulant treatment in patients with atrial fibrillation. TH Open. 2023;7(03):e270-e279. doi:10.1055/a-2161-0928.</mixed-citation><mixed-citation xml:lang="en">van der Horst SF, de Vries TA, Chu G, et al. Prevalence and predictors of nonadherence to direct oral anticoagulant treatment in patients with atrial fibrillation. TH Open. 2023;7(03):e270-e279. doi:10.1055/a-2161-0928.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Perreault S, de Denus S, White-Guay B, et al. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. Pharmacotherapy. 2020;40(1):40-54. doi:10.1002/phar.2350.</mixed-citation><mixed-citation xml:lang="en">Perreault S, de Denus S, White-Guay B, et al. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation. Pharmacotherapy. 2020;40(1):40-54. doi:10.1002/phar.2350.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Zielinski GD, van Rein N, Teichert M, et al. Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. Pharmacoepidemiol Drug Saf. 2021;30(8):1027-36. doi:10.1002/pds.5242.</mixed-citation><mixed-citation xml:lang="en">Zielinski GD, van Rein N, Teichert M, et al. Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. Pharmacoepidemiol Drug Saf. 2021;30(8):1027-36. doi:10.1002/pds.5242.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data. J Manag Care Spec Pharm. 2017;23(9):958-67. doi:10.18553/jmcp.2017.23.9.958.</mixed-citation><mixed-citation xml:lang="en">Brown JD, Shewale AR, Talbert JC. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data. J Manag Care Spec Pharm. 2017;23(9):958-67. doi:10.18553/jmcp.2017.23.9.958.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020;106(2):119-26. doi:10.1136/heartjnl-2019-315307.</mixed-citation><mixed-citation xml:lang="en">Banerjee A, Benedetto V, Gichuru P, et al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart. 2020;106(2):119-26. doi:10.1136/heartjnl-2019-315307.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Lapa ME, Swabe GM, Magnani JW. Association of Depression and Adherence to Oral Anticoagulation in Patients With Atrial Fibrillation. Journal of the American Heart Association. 2023;12(22):e031281. doi:10.1161/JAHA.123.031281.</mixed-citation><mixed-citation xml:lang="en">Lapa ME, Swabe GM, Magnani JW. Association of Depression and Adherence to Oral Anticoagulation in Patients With Atrial Fibrillation. Journal of the American Heart Association. 2023;12(22):e031281. doi:10.1161/JAHA.123.031281.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">McHorney CA, Ashton V, Laliberté F, et al. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017;23(9):980-8. doi:10.18553/jmcp.2017.23.9.980.</mixed-citation><mixed-citation xml:lang="en">McHorney CA, Ashton V, Laliberté F, et al. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. J Manag Care Spec Pharm. 2017;23(9):980-8. doi:10.18553/jmcp.2017.23.9.980.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobs MS, Schouten JF, de Boer PT, et al. Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. Curr Med Res Opin. 2018;34(10):1839-47. doi:10.1080/03007995.2018.1459528.</mixed-citation><mixed-citation xml:lang="en">Jacobs MS, Schouten JF, de Boer PT, et al. Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands. Curr Med Res Opin. 2018;34(10):1839-47. doi:10.1080/03007995.2018.1459528.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Coleman CI, Roberts MS, Sobieraj DM, et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28(5):669-80. doi:10.1185/03007995.2012.677419.</mixed-citation><mixed-citation xml:lang="en">Coleman CI, Roberts MS, Sobieraj DM, et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28(5):669-80. doi:10.1185/03007995.2012.677419.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419-34. doi:10.2147/PPA.S44646.</mixed-citation><mixed-citation xml:lang="en">Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013;7:419-34. doi:10.2147/PPA.S44646.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Weeda ER, Coleman CI, McHorney CA, et al. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: A metaregression analysis. Int J Cardiol. 2016;216:104-9. doi:10.1016/j.ijcard.2016.04.082.</mixed-citation><mixed-citation xml:lang="en">Weeda ER, Coleman CI, McHorney CA, et al. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: A metaregression analysis. Int J Cardiol. 2016;216:104-9. doi:10.1016/j.ijcard.2016.04.082.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Pham PN, Brown JD. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter? BMC Cardiovascular Disorders. 2019;19:1-10. doi:10.1186/s12872-019-1033-3.</mixed-citation><mixed-citation xml:lang="en">Pham PN, Brown JD. Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter? BMC Cardiovascular Disorders. 2019;19:1-10. doi:10.1186/s12872-019-1033-3.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Godinas L, Dobbels F, Hulst L, et al. Once daily tacrolimus conversion in lung transplantation: A prospective study on safety and medication adherence. J Heart Lung Transplant. 2021;40(6):467-77. doi:10.1016/j.healun.2021.02.017.</mixed-citation><mixed-citation xml:lang="en">Godinas L, Dobbels F, Hulst L, et al. Once daily tacrolimus conversion in lung transplantation: A prospective study on safety and medication adherence. J Heart Lung Transplant. 2021;40(6):467-77. doi:10.1016/j.healun.2021.02.017.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">de Llano LP, Sanmartin AP, González-Barcala FJ, et al. Assessing adherence to inhaled medication in asthma: Impact of once-daily versus twice-daily dosing frequency. The ATAUD study. J Asthma. 2018;55(9):933-8. doi:10.1080/02770903.2018.1426769.</mixed-citation><mixed-citation xml:lang="en">de Llano LP, Sanmartin AP, González-Barcala FJ, et al. Assessing adherence to inhaled medication in asthma: Impact of once-daily versus twice-daily dosing frequency. The ATAUD study. J Asthma. 2018;55(9):933-8. doi:10.1080/02770903.2018.1426769.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Elnaem MH, Irwan NA, Abubakar U, et al. Impact of Medication Regimen Simplification on Medication Adherence and Clinical Outcomes in Patients with Long-Term Medical Conditions. Patient Prefer Adherence. 2020;14:2135-45. doi:10.2147/PPA.S268499.</mixed-citation><mixed-citation xml:lang="en">Elnaem MH, Irwan NA, Abubakar U, et al. Impact of Medication Regimen Simplification on Medication Adherence and Clinical Outcomes in Patients with Long-Term Medical Conditions. Patient Prefer Adherence. 2020;14:2135-45. doi:10.2147/PPA.S268499.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Syed YY. Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use. Am J Cardiovasc Drugs. 2022;22(2):219-30. doi:10.1007/s40256-022-00521-0.</mixed-citation><mixed-citation xml:lang="en">Syed YY. Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use. Am J Cardiovasc Drugs. 2022;22(2):219-30. doi:10.1007/s40256-022-00521-0.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">McHorney CA, Peterson E, Ashton V, et al. Adherence to QD vs. BID Medications in NVAF Patients is Associated With Reduced Risk of Ischemic Stroke: A Modeling Study Using RCT and Claims Data. Circulation. 2016;134(suppl_1):A15087-A15087. doi:10.1161/circ.134.suppl_1.15087.</mixed-citation><mixed-citation xml:lang="en">McHorney CA, Peterson E, Ashton V, et al. Adherence to QD vs. BID Medications in NVAF Patients is Associated With Reduced Risk of Ischemic Stroke: A Modeling Study Using RCT and Claims Data. Circulation. 2016;134(suppl_1):A15087-A15087. doi:10.1161/circ.134.suppl_1.15087.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Туров А. Н., Панфилов С.В., Чиглинцева О.В. Эффективность, безопасность и приверженность при использовании новых антикоагулянтов у пациентов с фибрилляцией предсердий старше 75 лет. Рациональная Фармакотерапия в Кардиологии. 2020;16(1):10-8. doi:10.20996/1819-6446-2020-20-07.</mixed-citation><mixed-citation xml:lang="en">Turov AN, Panfilov SV, Tschiglinzeva ОV. The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation. Rational Pharmacotherapy in Cardiology. 2020;16(1):10-8. (In Russ.) doi:10.20996/1819-6446-2020-20-07.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
